pharmaceutical investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
pharmaceutical investing Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
Stallion Uranium Announces Flow-Through and Non-Flow Through Private Placements for Gross Proceeds of up to $12M
NextSource Materials Executes Binding Offtake Agreement with Mitsubishi Chemical Corporation to Supply SuperFlake Graphite Anode Material for the North American EV Market
SAGA Metals Confirms a 3 km Continuous Magnetic Anomaly in the Trapper Zone at the 100% Owned Radar Titanium Property in Labrador, Canada & Provides Corporate Update
